Cencora, Inc. $COR Shares Bought by Choreo LLC

Choreo LLC boosted its holdings in shares of Cencora, Inc. (NYSE:COR) by 12.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,223 shares of the company’s stock after purchasing an additional 479 shares during the quarter. Choreo LLC’s holdings in Cencora were worth $1,266,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Northwest & Ethical Investments L.P. purchased a new stake in Cencora in the 2nd quarter worth $2,701,000. Rhenman & Partners Asset Management AB grew its position in shares of Cencora by 52.5% in the second quarter. Rhenman & Partners Asset Management AB now owns 49,375 shares of the company’s stock valued at $14,805,000 after purchasing an additional 17,000 shares during the period. J.W. Cole Advisors Inc. increased its stake in shares of Cencora by 8.7% during the second quarter. J.W. Cole Advisors Inc. now owns 6,540 shares of the company’s stock worth $1,961,000 after purchasing an additional 522 shares in the last quarter. Elo Mutual Pension Insurance Co raised its position in shares of Cencora by 10.7% during the 2nd quarter. Elo Mutual Pension Insurance Co now owns 23,273 shares of the company’s stock worth $6,978,000 after purchasing an additional 2,259 shares during the last quarter. Finally, Laurel Wealth Advisors LLC lifted its stake in Cencora by 29,900.0% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 900 shares of the company’s stock valued at $270,000 after buying an additional 897 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 46,640 shares of company stock worth $14,099,338 over the last quarter. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Performance

Shares of Cencora stock opened at $368.93 on Friday. The business’s 50 day moving average price is $335.71 and its 200 day moving average price is $307.63. The company has a market cap of $71.53 billion, a price-to-earnings ratio of 37.96, a PEG ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a one year low of $223.92 and a one year high of $377.54.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period last year, the company earned $3.34 EPS. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s payout ratio is presently 30.19%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on COR shares. Robert W. Baird boosted their price objective on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research note on Friday. Wells Fargo & Company increased their price objective on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. JPMorgan Chase & Co. raised their price objective on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, TD Cowen lifted their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $371.09.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.